Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Liabilities: 2015-2025

Historic Other Non-Current Liabilities for Aytu Biopharma (AYTU) over the last 11 years, with Jun 2025 value amounting to $26.3 million.

  • Aytu Biopharma's Other Non-Current Liabilities rose 117.23% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 117.23%. This contributed to the annual value of $26.3 million for FY2025, which is 106.62% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Other Non-Current Liabilities is $26.3 million, which was up 106.62% from $12.7 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Other Non-Current Liabilities ranged from a high of $26.3 million in FY2025 and a low of $7.0 million during FY2023.
  • Its 3-year average for Other Non-Current Liabilities is $15.4 million, with a median of $12.7 million in 2024.
  • As far as peak fluctuations go, Aytu Biopharma's Other Non-Current Liabilities tumbled by 45.50% in 2023, and later skyrocketed by 106.62% in 2025.
  • Over the past 5 years, Aytu Biopharma's Other Non-Current Liabilities (MRY) stood at $18.5 million in 2021, then plummeted by 30.75% to $12.8 million in 2022, then plummeted by 45.50% to $7.0 million in 2023, then skyrocketed by 82.72% to $12.7 million in 2024, then soared by 106.62% to $26.3 million in 2025.
  • Its Other Non-Current Liabilities stands at $26.3 million for FY2025, versus $12.7 million for FY2024 and $7.0 million for FY2023.